{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T13:30:01Z","timestamp":1794922201910,"version":"4.9.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82360550"],"award-info":[{"award-number":["82360550"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82260555"],"award-info":[{"award-number":["82260555"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"crossref","award":["2022A1515012224"],"award-info":[{"award-number":["2022A1515012224"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Hepatocellular carcinoma (HCC) recurrence postresection represents a thorny problem in clinical practice, of which impaired natural killer (NK) cell cytotoxicity represents one of crucial causes. Apart from recurrence, hepatectomy-induced abdominal adhesion also poses huge clinical challenges such as abdominal pain, intestinal obstruction, and perforation. Evidence demonstrates that radiotherapy can upregulate NK group 2D ligand expression on tumor cells to enhance NK cell cytotoxicity, indicating its great potential of curbing HCC recurrence. Nevertheless, radiotherapy has also been disclosed to incur suppression on NK antitumor cell immunity. Herein, we reveal that glycocholic acid (GCA)\/tRNA-derived fragment 5 (tRF5)-GlyGCC signaling axis is activated in mouse HCC model after radiotherapy, which dampens NK cell antitumor immunity to limit therapeutic efficacy. Mechanistically, tRF5-GlyGCC can interact with KDM6B to epigenetically upregulate Runx2 and then transcriptionally activate ITGBL1 and S100A9 expression in HCC cells, which further reduces NK cell cytotoxicity directly and attracts myeloid-derived suppressor cell (MDSC) to inhibit NK cell function indirectly, respectively. Therefore, radiotherapy plus targeting tRF5-GlyGCC may be an optimized postoperative adjuvant therapy against HCC recurrence. Then, a nanocomposite powder is designed for liver-localized delivery of tRF5-GlyGCC inhibitor. After sprayed to liver resection margin of mouse HCC model, this powder can rapidly form an in-situ Janus-adhesive hydrogel, which allows for sustained delivery of tRF5-GlyGCC inhibitor. Importantly, it can synergize with radiotherapy to potentiate NK cell antitumor immunity and prevent HCC recurrence postresection. Moreover, its application to surgical bed also effectively mitigates abdominal adhesion in a rat hepatectomy model. Altogether, our work develops a tRF5-GlyGCC-targeting nanocomposite power for sensitizing radiotherapy to thwart HCC recurrence and preventing abdominal adhesion.<\/jats:p>\n          <jats:p>\n            <jats:bold>Graphical Abstract<\/jats:bold>\n          <\/jats:p>","DOI":"10.1186\/s12951-025-03133-3","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T10:52:12Z","timestamp":1739184732000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Radiotherapy plus a self-gelation powder encapsulating tRF5-GlyGCC inhibitor potentiates natural kill cell immunity to prevent hepatocellular carcinoma recurrence"],"prefix":"10.1186","volume":"23","author":[{"given":"Yihang","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanxin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoquan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haipeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusheng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeqian","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiangen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wence","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"issue":"3","key":"3133_CR1","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.livres.2023.07.003","volume":"7","author":"BI Carr","year":"2023","unstructured":"Carr BI, et al. Discordance among aggressiveness characteristics of hepatocellular carcinoma: portal vein thrombosis and multifocality, related to tumor size, but not to serum alpha-fetoprotein level. Liver Res. 2023;7(3):256\u201362.","journal-title":"Liver Res"},{"issue":"3","key":"3133_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"3133_CR3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.21037\/hbsn-21-223","volume":"11","author":"L Wang","year":"2022","unstructured":"Wang L, et al. The role of intraoperative electron radiotherapy in centrally located hepatocellular carcinomas treated with narrow-margin (<1 cm) hepatectomy: a prospective, phase 2 study. Hepatobiliary Surg Nutr. 2022;11(4):515\u201329.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"3133_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2022.110521","volume":"157","author":"L Zuo","year":"2022","unstructured":"Zuo L, et al. MRI-based preoperative markers combined with narrow-margin hepatectomy result in higher early recurrence. Eur J Radiol. 2022;157: 110521.","journal-title":"Eur J Radiol"},{"issue":"50","key":"3133_CR5","doi-asserted-by":"publisher","first-page":"32046","DOI":"10.1073\/pnas.2012491117","volume":"117","author":"E Zhang","year":"2020","unstructured":"Zhang E, et al. Fouling-resistant zwitterionic polymers for complete prevention of postoperative adhesion. Proc Natl Acad Sci USA. 2020;117(50):32046\u201355.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"3133_CR6","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/cmi.2015.96","volume":"13","author":"H Peng","year":"2016","unstructured":"Peng H, Wisse E, Tian Z. Liver natural killer cells: subsets and roles in liver immunity. Cell Mol Immunol. 2016;13(3):328\u201336.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"3133_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000301","volume":"8","author":"DJ Park","year":"2020","unstructured":"Park DJ, et al. EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1. J Immunother Cancer. 2020;8(1): e000301.","journal-title":"J Immunother Cancer"},{"key":"3133_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121506","volume":"284","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, et al. Injectable adhesive hemostatic gel with tumor acidity neutralizer and neutrophil extracellular traps lyase for enhancing adoptive NK cell therapy prevents post-resection recurrence of hepatocellular carcinoma. Biomaterials. 2022;284: 121506.","journal-title":"Biomaterials"},{"issue":"23","key":"3133_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202201271","volume":"9","author":"Y Gong","year":"2022","unstructured":"Gong Y, et al. An Injectable epigenetic autophagic modulatory hydrogel for boosting umbilical cord blood NK cell therapy prevents postsurgical relapse of triple-negative breast cancer. Adv Sci. 2022;9(23): e2201271.","journal-title":"Adv Sci"},{"issue":"6","key":"3133_CR10","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.jhep.2021.01.017","volume":"74","author":"M Cadoux","year":"2021","unstructured":"Cadoux M, et al. Expression of NKG2D ligands is downregulated by \u03b2-catenin signalling and associates with HCC aggressiveness. J Hepatol. 2021;74(6):1386\u201397.","journal-title":"J Hepatol"},{"issue":"1","key":"3133_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","volume":"12","author":"FG Herrera","year":"2022","unstructured":"Herrera FG, et al. Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy. Cancer Discov. 2022;12(1):108\u201333.","journal-title":"Cancer Discov"},{"issue":"4","key":"3133_CR12","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1158\/1078-0432.CCR-17-1766","volume":"24","author":"T Weiss","year":"2018","unstructured":"Weiss T, et al. NKG2D-dependent antitumor effects of chemotherapy and radiotherapy against glioblastoma. Clin Cancer Res. 2018;24(4):882\u201395.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3133_CR13","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1002\/hep.31993","volume":"74","author":"B Chen","year":"2021","unstructured":"Chen B, et al. Phase 2 study of adjuvant radiotherapy following narrow-margin hepatectomy in patients with HCC. Hepatology. 2021;74(5):2595\u2013604.","journal-title":"Hepatology"},{"key":"3133_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2022.109462","volume":"180","author":"L Long","year":"2023","unstructured":"Long L, et al. Survival benefit of radiotherapy following narrow-margin hepatectomy in patients with hepatocellular carcinoma: a propensity score-matched analysis based on phase II study. Radiother Oncol. 2023;180: 109462.","journal-title":"Radiother Oncol"},{"key":"3133_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.canlet.2020.12.045","volume":"502","author":"NE Donlon","year":"2021","unstructured":"Donlon NE, et al. Radiotherapy, immunotherapy, and the tumour microenvironment: turning an immunosuppressive milieu into a therapeutic opportunity. Cancer Lett. 2021;502:84\u201396.","journal-title":"Cancer Lett"},{"issue":"15","key":"3133_CR16","volume":"11","author":"J Ji","year":"2024","unstructured":"Ji J, et al. Radiotherapy-induced astrocyte senescence promotes an immunosuppressive microenvironment in glioblastoma to facilitate tumor regrowth. Adv Sci (Weinheim, Baden-Wurttemberg, Germany). 2024;11(15): e2304609.","journal-title":"Adv Sci (Weinheim, Baden-Wurttemberg, Germany)"},{"key":"3133_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2024.11.003","author":"T Zhuang","year":"2024","unstructured":"Zhuang T, et al. Biological functions and pharmacological behaviors of bile acids in metabolic diseases. J Adv Res. 2024. https:\/\/doi.org\/10.1016\/j.jare.2024.11.003.","journal-title":"J Adv Res"},{"issue":"6","key":"3133_CR18","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/j.jhep.2021.01.028","volume":"74","author":"L Conde de la Rosa","year":"2021","unstructured":"Conde de la Rosa L, et al. STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway. J Hepatol. 2021;74(6):1429\u201341.","journal-title":"J Hepatol"},{"issue":"2","key":"3133_CR19","first-page":"144","volume":"21","author":"Y Song","year":"2023","unstructured":"Song Y, et al. Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma. Cancer Biol Med. 2023;21(2):144\u201362.","journal-title":"Cancer Biol Med"},{"key":"3133_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.711448","volume":"11","author":"Y Gong","year":"2021","unstructured":"Gong Y, et al. Norcholic acid promotes tumor progression and immune escape by regulating farnesoid X receptor in hepatocellular carcinoma. Front Oncol. 2021;11: 711448.","journal-title":"Front Oncol"},{"key":"3133_CR21","doi-asserted-by":"publisher","first-page":"1095915","DOI":"10.3389\/fimmu.2022.1095915","volume":"13","author":"H Gou","year":"2022","unstructured":"Gou H, et al. Obeticholic acid and 5\u03b2-cholanic acid 3 exhibit anti-tumor effects on liver cancer through CXCL16\/CXCR6 pathway. Front Immunol. 2022;13:1095915.","journal-title":"Front Immunol"},{"issue":"5","key":"3133_CR22","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41580-023-00690-z","volume":"25","author":"S Muthukumar","year":"2024","unstructured":"Muthukumar S, et al. Roles and regulation of tRNA-derived small RNAs in animals. Nat Rev Mol Cell Biol. 2024;25(5):359\u201378.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"8","key":"3133_CR23","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/ijc.35041","volume":"155","author":"J Lu","year":"2024","unstructured":"Lu J, et al. tRNA-derived fragments: unveiling new roles and molecular mechanisms in cancer progression. Int J Cancer. 2024;155(8):1347\u201360.","journal-title":"Int J Cancer"},{"issue":"9","key":"3133_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009552","volume":"12","author":"FG \u00d6zbay Kurt","year":"2024","unstructured":"\u00d6zbay Kurt FG, et al. S100A9 and HMGB1 orchestrate MDSC-mediated immunosuppression in melanoma through TLR4 signaling. J Immunother Cancer. 2024;12(9): e009552.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"3133_CR25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12943-020-01306-2","volume":"20","author":"Y Cheli","year":"2021","unstructured":"Cheli Y, et al. ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity. Mol Cancer. 2021;20(1):12.","journal-title":"Mol Cancer"},{"issue":"1","key":"3133_CR26","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1186\/s12951-024-02756-2","volume":"22","author":"Z Wu","year":"2024","unstructured":"Wu Z, et al. Tea polyphenol nanoparticles enable targeted siRNA delivery and multi-bioactive therapy for abdominal aortic aneurysms. J Nanobiotechnol. 2024;22(1):471.","journal-title":"J Nanobiotechnol"},{"key":"3133_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121485","volume":"284","author":"F Liu","year":"2022","unstructured":"Liu F, et al. LncRNA-targeting bio-scaffold mediates triple immune effects for postoperative colorectal cancer immunotherapy. Biomaterials. 2022;284: 121485.","journal-title":"Biomaterials"},{"issue":"4","key":"3133_CR28","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41556-021-00652-7","volume":"23","author":"J Shi","year":"2021","unstructured":"Shi J, et al. PANDORA-seq expands the repertoire of regulatory small RNAs by overcoming RNA modifications. Nat Cell Biol. 2021;23(4):424\u201336.","journal-title":"Nat Cell Biol"},{"issue":"29","key":"3133_CR29","doi-asserted-by":"publisher","first-page":"24638","DOI":"10.1021\/acsami.8b07570","volume":"10","author":"M Liu","year":"2018","unstructured":"Liu M, et al. Hypoxia-triggered nanoscale metal-organic frameworks for enhanced anticancer activity. ACS Appl Mater Interfaces. 2018;10(29):24638\u201347.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"13","key":"3133_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202109726","volume":"34","author":"Y Wang","year":"2022","unstructured":"Wang Y, et al. High-Z-sensitized radiotherapy synergizes with the intervention of the pentose phosphate pathway for in situ tumor vaccination. Adv Mater (Deerfield Beach, Fla). 2022;34(13): e2109726.","journal-title":"Adv Mater (Deerfield Beach, Fla)."},{"issue":"1","key":"3133_CR31","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-022-01270-y","volume":"15","author":"W Yang","year":"2022","unstructured":"Yang W, et al. A novel tRNA-derived fragment AS-tDR-007333 promotes the malignancy of NSCLC via the HSPB1\/MED29 and ELK4\/MED29 axes. J Hematol Oncol. 2022;15(1):53.","journal-title":"J Hematol Oncol"},{"issue":"21","key":"3133_CR32","doi-asserted-by":"publisher","DOI":"10.1172\/JCI175147","volume":"134","author":"S Hamze Sinno","year":"2024","unstructured":"Hamze Sinno S, et al. Egfl6 promotes ovarian cancer progression by enhancing the immunosuppressive functions of tumor-associated myeloid cells. J Clin Investig. 2024;134(21): e175147.","journal-title":"J Clin Investig"},{"key":"3133_CR33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.canlet.2021.01.011","volume":"503","author":"W Wang","year":"2021","unstructured":"Wang W, et al. Tumor-associated mesenchymal stem cells promote hepatocellular carcinoma metastasis via a DNM3OS\/KDM6B\/TIAM1 axis. Cancer Lett. 2021;503:19\u201331.","journal-title":"Cancer Lett"},{"issue":"10","key":"3133_CR34","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000277","volume":"7","author":"M Hatano","year":"2023","unstructured":"Hatano M, et al. Loss of KDM6B epigenetically confers resistance to lipotoxicity in nonalcoholic fatty liver disease-related HCC. Hepatol Commun. 2023;7(10): e0277.","journal-title":"Hepatol Commun"},{"issue":"1","key":"3133_CR35","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13148-022-01305-8","volume":"14","author":"J Abu-Hanna","year":"2022","unstructured":"Abu-Hanna J, et al. Therapeutic potential of inhibiting histone 3 lysine 27 demethylases: a review of the literature. Clin Epigenetics. 2022;14(1):98.","journal-title":"Clin Epigenetics"},{"key":"3133_CR36","first-page":"273","volume":"25","author":"Y Yang","year":"2023","unstructured":"Yang Y, et al. Triple-functional bone adhesive with enhanced internal fixation, bacteriostasis and osteoinductive properties for open fracture repair. Bioact Mater. 2023;25:273\u201390.","journal-title":"Bioact Mater"},{"issue":"10","key":"3133_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202105783","volume":"34","author":"J Yan","year":"2022","unstructured":"Yan J, et al. Engineering radiosensitizer-based metal-phenolic networks potentiate STING pathway activation for advanced radiotherapy. Adv Mater (Deerfield Beach, Fla). 2022;34(10): e2105783.","journal-title":"Adv Mater (Deerfield Beach, Fla)"},{"issue":"3","key":"3133_CR38","doi-asserted-by":"publisher","first-page":"629","DOI":"10.4049\/jimmunol.2100044","volume":"209","author":"NG Battaglia","year":"2022","unstructured":"Battaglia NG, et al. Combination of NKG2A and PD-1 blockade improves radiotherapy response in radioresistant tumors (Baltimore, Md.: 1950). J Immunol. 2022;209(3):629\u201340.","journal-title":"J Immunol"},{"issue":"11","key":"3133_CR39","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/bjs.7657","volume":"98","author":"BWJ Hellebrekers","year":"2011","unstructured":"Hellebrekers BWJ, Kooistra T. Pathogenesis of postoperative adhesion formation. Br J Surg. 2011;98(11):1503\u201316.","journal-title":"Br J Surg"},{"key":"3133_CR40","first-page":"387","volume":"26","author":"J Liao","year":"2023","unstructured":"Liao J, Li X, Fan Y. Prevention strategies of postoperative adhesion in soft tissues by applying biomaterials: based on the mechanisms of occurrence and development of adhesions. Bioact Mater. 2023;26:387\u2013412.","journal-title":"Bioact Mater"},{"key":"3133_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2024.101248","volume":"28","author":"H Shao","year":"2024","unstructured":"Shao H, et al. A Janus hydrogel that enables wet tissue adhesion and resists abdominal adhesions. Mater Today Bio. 2024;28: 101248.","journal-title":"Mater Today Bio"},{"key":"3133_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202403753","volume":"20","author":"Z Ding","year":"2024","unstructured":"Ding Z, et al. Janus-structured microgel barrier with tissue adhesive and hemostatic characteristics for efficient prevention of postoperative adhesion. Small. 2024;20: e2403753.","journal-title":"Small"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03133-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-025-03133-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03133-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T11:33:14Z","timestamp":1739187194000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-025-03133-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3133"],"URL":"https:\/\/doi.org\/10.1186\/s12951-025-03133-3","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"assertion":[{"value":"27 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received the Animal Care and Use Committee of Jennio Biotech Co.,Ltd (IACUC-2024-A037).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have approved the manuscript and agree for the submission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"100"}}